Lo Jennifer A, Fisher David E
Cutaneous Biology Research Center, Department of Dermatology and MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Science. 2014 Nov 21;346(6212):945-9. doi: 10.1126/science.1253735.
Melanoma, the deadliest form of skin cancer, is an aggressive disease that is rising in incidence. Although melanoma is a historically treatment-resistant malignancy, in recent years unprecedented breakthroughs in targeted therapies and immunotherapies have revolutionized the standard of care for patients with advanced disease. Here, we provide an overview of recent developments in our understanding of melanoma risk factors, genomics, and molecular pathogenesis and how these insights have driven advances in melanoma treatment. In addition, we review benefits and limitations of current therapies and look ahead to continued progress in melanoma prevention and therapy. Remarkable achievements in the field have already produced a paradigm shift in melanoma treatment: Metastatic melanoma, once considered incurable, can now be treated with potentially curative rather than palliative intent.
黑色素瘤是皮肤癌中最致命的一种,是一种侵袭性疾病,其发病率正在上升。尽管黑色素瘤历来是一种对治疗有抗性的恶性肿瘤,但近年来,靶向治疗和免疫治疗取得了前所未有的突破,彻底改变了晚期疾病患者的护理标准。在此,我们概述了近期在黑色素瘤风险因素、基因组学和分子发病机制方面的认识进展,以及这些见解如何推动了黑色素瘤治疗的进步。此外,我们回顾了当前疗法的益处和局限性,并展望黑色素瘤预防和治疗方面的持续进展。该领域的显著成就已经在黑色素瘤治疗中产生了范式转变:转移性黑色素瘤,曾经被认为无法治愈,现在可以用潜在的治愈性而非姑息性意图进行治疗。